Literature DB >> 2018562

Differential effects of neonatally administered glutamate on the ultradian pattern of circulating growth hormone regulating expression of sex-dependent forms of cytochrome P450.

N A Pampori1, A K Agrawal, D J Waxman, B H Shapiro.   

Abstract

Neonatal male rats were treated with monosodium glutamate (MSG) at either 0.5, 1.0, 2.0, 3.0 or 4.0 mg/g body weight on alternate days during the first 9 days of life. As adults, rats were catheterized to obtain unstressed, serial blood samples for the determination of ultradian patterns of circulating growth hormone. In addition, the levels of drug-metabolizing enzymes (i.e. hexobarbital hydroxylase, cytochromes P450 and b5, NADPH-cytochrome P450 reductase and ethoxyresorufin O-deethylase) as well as sex-dependent forms of cytochrome P450 [i.e. male-dependent cytochromes P450 2c (IIC11), 2a (IIIA2) and RLM2 (IIA2) and female-dependent cytochromes P450 2d (IIC12) and 3 (IIA1)] and/or their catalytic activities were measured in the hepatic microsomes of the treated rats. The results demonstrated a dose-dependent, graded response to MSG treatment. As the dose of MSG increased from 0.5 to 4.0 mg, there was a concurrent decline in the amplitudes of the characteristically masculine, episodic bursts of growth hormone, until at the highest dose (4 mg), the pulses were no longer detectable. Associated with this dose-dependent alteration in the ultradian pattern of growth hormone secretion was a measurable change in the activities of the sex-dependent hepatic enzymes. As the pulse heights of the hormone declined to 10-20% of their normal amplitudes, the levels of the male-dependent enzymes (i.e. the drug-metabolizing enzymes, as well as the male forms of cytochrome P450 and their specific steroid hydroxylases) were maintained, and in some cases, exceeded the levels normally found in males. However, as the hormone pulse heights declined, there appeared an accompanying increase in the activities of some of the female-dependent enzymes. Finally, with the loss of all detectable levels of circulating growth hormone, the normal masculine profile of hepatic enzymes was reversed to an apparently normal (with the exception of cytochrome P450 2d) feminine profile. Summarizing, the results indicate that (1) neonatal administration of MSG can produce dose-dependent, graded, long-term developmental defects in the ultradian rhythm of circulating growth hormone and associated sex-dependent hepatic enzymes, and (2) while the male-dependent hepatic enzymes can be maintained at normal or even higher levels in the face of an up to 90% reduction in the pulse heights of plasma growth hormone, the activities of the female-dependent enzymes may begin to increase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018562     DOI: 10.1016/0006-2952(91)90101-a

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Growth hormone: a newly identified developmental organizer.

Authors:  Rajat K Das; Sarmistha Banerjee; Bernard H Shapiro
Journal:  J Endocrinol       Date:  2016-12-15       Impact factor: 4.286

2.  Feminization imprinted by developmental growth hormone.

Authors:  Sarmistha Banerjee; Rajat K Das; Bernard H Shapiro
Journal:  Mol Cell Endocrinol       Date:  2018-08-29       Impact factor: 4.102

3.  Permanent uncoupling of male-specific CYP2C11 transcription/translation by perinatal glutamate.

Authors:  Sarmistha Banerjee; Rajat Kumar Das; Kelly A Giffear; Bernard H Shapiro
Journal:  Toxicol Appl Pharmacol       Date:  2015-02-16       Impact factor: 4.219

4.  Irreversible perinatal imprinting of adult expression of the principal sex-dependent drug-metabolizing enzyme CYP2C11.

Authors:  Rajat Kumar Das; Sarmistha Banerjee; Bernard H Shapiro
Journal:  FASEB J       Date:  2014-06-18       Impact factor: 5.191

5.  Early expression of requisite developmental growth hormone imprinted cytochromes P450 and dependent transcription factors.

Authors:  Sarmistha Banerjee; Allison M Hayes; Bernard H Shapiro
Journal:  Endocr Connect       Date:  2021-09-20       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.